What is claimed is:

1. Use of a compound of general formula (I) or a pharmaceutically acceptable salt, a stereoisomer and a crystal form thereof in the preparation of a medicament for treating biliary tract cancer:



(I)

wherein Ar is phenyl optionally substituted with 1–3 $R_6$, each $R_6$ is independently selected from hydrogen, amino, cyano, halogen, $C_{1-4}$ alkyl and trifluoromethyl;

Y is $CR_3$;

P is $CR_4$;

W is N;

$R_3$ is hydrogen or $C_{1-4}$ alkyl;

$R_4$ is -$(CH_2)_n$-(5-11) membered heterocyclyl, wherein n = 0–6, a ring-forming S atom in the heterocyclyl is optionally oxidized to S(O) or $S(O)_2$, a ring-forming C atom in the heterocyclyl is optionally oxidized to C(O), and the heterocyclyl is optionally substituted with one to more substituents independently selected from $C_{1-3}$ alkyl and $C_{3-6}$ cycloalkyl.

2. The use according to claim 1,

wherein Ar is phenyl optionally substituted with 1–3 $R_6$, and each $R_6$ is independently selected from hydrogen and halogen;

Y is $CR_3$;

P is $CR_4$;

W is N;

$R_3$ is hydrogen;

$R_4$ is selected from -$(CH_2)_n$-(5-6) membered monocyclic heterocyclyl and -$(CH_2)_n$-(7-11) membered fused heterocyclyl, wherein n = 0–6, a ring-forming S atom in the heterocyclyl is optionally oxidized to S(O) or $S(O)_2$, a ring-forming C atom is optionally oxidized to C(O), and the heterocyclyl is optionally substituted with one to more

substituents independently selected from $C_{1-3}$ alkyl and $C_{3-6}$ cycloalkyl.

3. The use according to claim 2, wherein

$R_4$ is , , , , , , , , , , or , and n = 0–3, wherein the heterocyclyl is optionally substituted with one to more substituents independently selected from $C_{1-3}$ alkyl and $C_{3-6}$ cycloalkyl.

4. The use according to claim 3, wherein the compound is selected from compounds of the following structures, and a pharmaceutically acceptable salt, a stereoisomer and a crystal form thereof:

, , ,

, , ,

, , ,


,

,

,

,

,

,

,

,

,

, (S)

, (R)
, and

.

5. The use according to claim 4, wherein the compound is  or a pharmaceutically acceptable salt, a stereoisomer, and a crystal form thereof.

6. The use according to any one of claims 1 to 5, wherein the biliary tract cancer is cholangiocarcinoma, preferably an FGFR-mediated cholangiocarcinoma, and further preferably cholangiocarcinoma mediated by any one of FGFR1, FGFR2 and FGFR3 or any combination thereof.

7. The use according to claim 6, wherein the cholangiocarcinoma is a cholangiocarcinoma with non-FGFR aberration.

8. The use according to claim 6, wherein the cholangiocarcinoma is a cholangiocarcinoma with FGFR aberration, and preferably a cholangiocarcinoma with FGFR2 aberration and/or a cholangiocarcinoma with FGFR3 aberration.

9. The use according to claim 8, wherein the cholangiocarcinoma is cholangiocarcinoma with any one of FGFR fusion, FGFR mutation and FGFR overexpression or any combination thereof.

10. The use according to claim 9, wherein the cholangiocarcinoma is cholangiocarcinoma with any one of FGFR2 fusion, FGFR2 and/or FGFR3 mutation and FGFR overexpression or any combination thereof.

11. The use according to claim 6, wherein the cholangiocarcinoma refers to drug-resistant cholangiocarcinoma that is positive for FGFR aberration but not responsive to an FGFR inhibitor, or drug-resistant cholangiocarcinoma after administration of an FGFR inhibitor.

12. The use according to claim 6, wherein the cholangiocarcinoma is any one of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and distal cholangiocarcinoma or any combination thereof.

13. The use according to any one of claims 1 to 5, wherein the medicament for treating biliary tract cancer further comprises a pharmaceutically acceptable carrier in addition to the compound of general formula (I) or the pharmaceutically acceptable salt, the stereoisomer and a crystal form thereof.

14. The use according to any one of claims 1 to 5, wherein the medicament for treating biliary tract cancer further comprises one or more second therapeutically active agents in addition to the compound of general formula (I) or the pharmaceutically acceptable salt, the stereoisomer and the crystal form thereof, wherein the one or more second therapeutically active agents are any one of an antimetabolite, a growth factor inhibitor, a mitotic inhibitor, an anti-tumor hormone, an alkylating agent, metallic platinum, a topoisomerase inhibitor, a hormonal agent, an immunomodulator, a tumor suppressor gene, a cancer vaccine and an immune checkpoint inhibitor or any combination thereof.